Publication date: Sep 01, 2024
Mobile health applications called Digital Adherence Technologies (DATs), are increasingly used for improving treatment adherence among Tuberculosis patients to attain cure, and/or other chronic diseases requiring long-term and complex medication regimens. These DATs are found to be useful in resource-limited settings because of their cost efficiency in reaching out to vulnerable groups (providing pill and clinic visit reminders, relevant health information, and motivational messages) or those staying in remote or rural areas. Despite their growing ubiquity, there is very limited evidence on how DATs improve healthcare outcomes. We analyzed the uptake of DATs in an urban setting (DS-DOST, powered by Connect for LifeTM, Johnson & Johnson) among different patient groups accessing TB services in New Delhi, India, and subsequently assessed its impact in improving patient engagement and treatment outcomes. This study aims to understand the uptake patterns of a digital adherence technology and its impact in improving follow-ups and treatment outcomes among TB patients. Propensity choice modelling was used to create balanced treated and untreated patient datasets, before applying simple ordinary least square and logistic regression methods to estimate the causal impact of the intervention on the number of follow-ups made with the patient and treatment outcomes. After controlling for potential confounders, it was found that patients who installed and utilized DS-DOST application received an average of 6. 4 (95% C. I. [5. 32 to 7. 557]) additional follow-ups, relative to those who did not utilize the application. This translates to a 58% increase. They also had a 245% higher likelihood of treatment success (Odds ratio: 3. 458; 95% C. I. [1. 709 to 6. 996]).
Open Access PDF
Concepts | Keywords |
---|---|
Clinic | |
Motivational | |
Pilot | |
Rural |
Semantics
Type | Source | Name |
---|---|---|
disease | IDO | intervention |
disease | MESH | Tuberculosis |
pathway | KEGG | Tuberculosis |
disease | MESH | chronic diseases |
drug | DRUGBANK | Spinosad |
drug | DRUGBANK | Coenzyme M |
drug | DRUGBANK | Trestolone |
pathway | REACTOME | Reproduction |
drug | DRUGBANK | Cysteamine |
drug | DRUGBANK | Isoxaflutole |
drug | DRUGBANK | Pentaerythritol tetranitrate |
disease | MESH | tic |
disease | MESH | adverse drug reactions |
disease | MESH | community transmission |
disease | IDO | country |
disease | IDO | facility |
drug | DRUGBANK | Etoperidone |
disease | MESH | COVID 19 pandemic |
disease | MESH | death |
disease | MESH | treatment failure |
drug | DRUGBANK | Methionine |
drug | DRUGBANK | Gold |
disease | IDO | algorithm |
disease | IDO | history |
drug | DRUGBANK | Ranitidine |
drug | DRUGBANK | Cobalt |
disease | IDO | process |